Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Next Generation Drug Conjugates Market 2026-2035 - Expansion into Non-Oncology Therapeutic Areas Present Opportunities for the $15.75 Billion Market

globenewswire.com
AZN AstraZeneca is a key market contributor and provides strong support for the Enhertu product segment, which dominates the next-generation drug conjugates market due to its efficacy and market penetration. PFE Pfizer is mentioned as a major market contributor in North America, indicating its presence and potential role in the growing drug conjugates market. NVS Novartis is identified as a major market contributor in North America, suggesting its involvement and potential growth within the expanding drug conjugates market. ALNY Alnylam Pharmaceuticals is listed as a major market contributor in North America, indicating its participation in the growing drug conjugates market.

Next Generation Drug Conjugates Market 2026-2035 - Expansion into Non-Oncology Therapeutic Areas Present Opportunities for the $15.75 Billion Market Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Next Generation Drug Conjugates Market by Product, Type, Target Ligand, Payload Type, Indication - Global Forecast to 2035" has been added to ResearchAndMarkets.com's offering.

The global next-generation drug conjugates market is set to expand from USD 15.75 billion in 2026 to USD 42.55 billion by 2035, growing at a CAGR of 11.7% during this period. This growth is driven by the surge in targeted therapies, continuous advancements in linker, payload, and targeting ligand technologies, and increased investments in oncology-focused drug innovations.

Active industry players are fostering double-digit growth projected through 2034, primarily due to strong clinical and commercial momentum. Nonetheless, challenges like safety issues, manufacturing complexity, and high treatment costs may hinder broader market expansion.

The Enhertu product segment leads in the next generation drug conjugates market in 2025

Key market segments include Enhertu (fam-trastuzumab deruxtecan-nxki), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Amvuttra (vutrisiran), Trodelvy (sacituzumab govitecan-hziy), and others. The ENHERTU product segment dominated the market in 2025 due to its potent efficacy across HER2-expressing tumors, swift label expansions beyond metastatic breast cancer, robust global market penetration, and strong support from AstraZeneca and Daiichi Sankyo.

The antibody-small molecule drug conjugate segment captures the largest market share by type in 2025

This segment includes antibody-small molecule, ligand-oligonucleotide, small molecule-radionuclide, and peptide-radionuclide conjugates. Antibody-drug conjugates are the most well-established and advanced class, furthering technological progress and improving treatment outcomes across diverse tumor types.

North America experiences the highest CAGR in the next generation drug conjugates market from 2026 to 2035

North America's robust growth is attributed to a concentration of biopharmaceutical innovation, early adoption of advanced therapies, and the presence of major market contributors like Novartis, Pfizer, and Alnylam.

Research Insights

The study segments the market by product, type, targeting ligand, payload type, indications, and region. It provides a comprehensive analysis of key market factors, including drivers, challenges, opportunities, and restraints. Detailed competitive analysis of top industry players is included, featuring product approvals, collaborations, and innovative strategies.

Leading Companies Profiled:

Key Attributes

Market Dynamics

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/fa0vk5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment